ResoTher Pharma announces encouraging top-line results from its Phase 2a clinical study of RTP-026 in patients with severe ST-elevation myocardial infarction (STEMI). RTP-026 was safe and well tolerated, with several parameters pointing towards a positive treatment effect on post-PCI infarct size and cardiac function.

Read the full press release here: RTP-026 SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS